应《网络安全法》要求，自2017年10月1日起，未进行实名认证将不得使用互联网跟帖服务。为保障您的帐号能够正常使用，请尽快对帐号进行手机号验证，感谢您的理解与支持！

24小时热门版块排行榜    

小木虫论坛-学术科研互动平台 » 生物医药区 » 新药研发 » 立项调研 » 达比加群酯的SWOT分析项
51/1返回列表
查看: 3824  |  回复: 17
只看楼主 @他人 存档 新回复提醒 (忽略) 收藏    在APP中查看
当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

williamxiang

木虫 (著名写手)

[交流] 达比加群酯的SWOT分析项

老大让我做一个SWOT分析，这对一个没有THOMSON、没有Pharmaproject的立项工作者来说，只能空手套白狼了，暂时只想出以下几个分析项，请各位虫友补充啦。
S分析
用药方法的便利性
出血安全性得到FDA、EMA等机构的屡次肯定
曾经获得FDA下属委员会全票支持
其对卒中的预防效果明显优于华法林
有间接比较研究显示，达比加群酯的成本-效益特征与有效性特征优于利伐沙班
先后在德国和加拿大被授予Prix Galien最佳药物奖
曾经获得NICE的有条件推荐
上市后市场表现强劲，已经实现了重磅炸弹级别的销售额
W分析
出血事件—达比加群酯挥之不去的阴影
肾功能损伤与P-gp是达比加群酯在其用药过程中需要调整剂量的主要因素
RE-ALLGN失败，使得人工心脏瓣膜成为达比加群酯的禁忌症之一
价格昂贵
O分析
适应证发病率高，用药市场规模庞大
需要开发新的药物，以弥补华法林的不足
利伐沙班于ROCKET-AF试验中仅证实与华法林相比的非劣性
T分析
将面临来自阿哌沙班、利伐沙班、依度沙班的激烈竞争

[ Last edited by williamxiang on 2013-4-3 at 16:31 ]
回复此楼

» 收录本帖的淘帖专辑推荐

研发工艺 泮托拉唑

» 猜你喜欢

» 本主题相关价值贴推荐，对您同样有帮助:

» 抢金币啦！回帖就可以得到:

查看全部散金贴
1楼 2013-04-03 10:21:39
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

smiler025

木虫 (著名写手)
★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
Weaknesses
A superiority claim over warfarin in stroke prevention was rejected for inclusion in the label by the FDA
A 110 mg doseage was not approved for use in patients at higher bleeding risk  
A higher risk of myocardial infarction was seen in RE-LY
Twice daily dosing, compared with once daily for Xarelto  
Not approved in the US for VTE prevention post-surgery, unlike Xarelto which was approved in July 2011
Has faced some safety concerns, and the label was updated to mandate renal testing in high-risk patients
Associated with a 6% rate of major gastrointestinal hemorrhage during each patient year on treatment
Other gastrointestinal side effects, including dyspepsia, nausea and gastritis, are increased compared with warfarin (35% vs 24%)
Current lack of antidote
Very short half-life once removed from specially designed desiccant-containing packaging
赞一下 回复此楼
3楼2013-04-03 10:41:12
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
查看全部 18 个回答

smiler025

木虫 (著名写手)
★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
Strengths
The first novel anticoagulant to secure approval for stroke prevention in atrial fibrillation (AF), entering the US market in November 2010
No requirement for anticoagulation monitoring and dose adjustment, and no food effect  
In the RE-LY trial in AF, Pradaxa showed comparable to superior efficacy in stroke prevention, compared with warfarin, with equal to lower bleeding risk
A subgroup analysis from RE-LY showed that Pradaxa 150 mg bid reduced the rate of stroke by 35% compared with well-controlled warfarin, irrespective of a patient's stroke risk  
Comparable to Lovenox in the prevention of major venous thromboembolism (VTE) and VTE-related mortality after both knee and hip replacement, according to RE-NOVATE data  
Equal efficacy to well-controlled warfarin in the treatment of acute VTE, but with a 37% reduction in major or clinically relevant bleeding risk over 6 months, according to RECOVER data
赞一下(1人) 回复此楼
2楼2013-04-03 10:38:46
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

smiler025

木虫 (著名写手)
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
Opportunities
Approval in AF opens up a blockbuster market, and Pradaxa could garner a greater share of the market in the near term due to its first mover advantage
Pradaxa could be viewed as superior to Xarelto given Xarelto's lack of superiority to warfarin on an intent-to-treat basis seen in the ROCKET AF trial
Despite the proven efficacy of warfarin in stroke prevention, it has a number of limitations, such as an increased risk of bleeding and the need for patient monitoring and dose adjustment, which has created an unmet need for safe and effective alternatives
Approval in acute coronary syndrome (ACS); phase III trials in this setting began in December 2007
Development of competitor Eliquis in ACS was discontinued following high rates of bleeding in trials
High cost and considerable copay required for Pradaxa may fade as insurers realize potential savings from increased avoidance of ischemic events and hospitalization
AF is the most common sustained cardiac rhythm disturbance, and prevalence increases with age
Up to 60% of cases of AF are caused by hypertension or coronary artery disease, which are increasing in prevalence in most Western societies
ACS is the leading cause of death in the US and one of the most prevalent non-communicable diseases in the world
赞一下 回复此楼
4楼2013-04-03 10:53:35
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

smiler025

木虫 (著名写手)
★ ★ ★ ★
williamxiang: 金币+4 2013-04-03 13:01:31
Threats
Commercial threat from Eliquis; current phase III data appear to support a superiority claim over warfarin which would differentiate the product
Increased competition in the oral anticoagulant category; the marketing battle between Pradaxa, Xarelto and Eliquis will be key
In Japan, Lixiana is in development for stroke prevention in AF, and could present competition in this market following Pradaxa's launch in March 2011
The drug may not gain approval in ACS given concerns about bleeding
If approved, use in ACS may be limited given the availability of new, more potent antiplatelet regimes, such as AstraZeneca's Brilinta, that improve outcomes with less increased bleeding
Physicians may be reluctant to switch patients who are well controlled on warfarin to other treatment options
Price: the significant price difference between Pradaxa and warfarin could present reimbursement issue
Self administration of low-molecular-weight heparins out of hospital by patients with AF undergoing elective cardioversion is a promising approach that may result in cost savings
Low-molecular-weight heparins, in particular enoxaparin which presents a generic and efficacious option for DVT treatment and prophylaxis following orthopedic surgery
赞一下 回复此楼
5楼2013-04-03 10:54:50
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
查看全部 18 个回答
普通表情 龙 兔 虎 猫 高级回复 (可上传附件)
信息提示
关闭
请填处理意见
关闭